Search

everythinglearnresearchcommunity

for

Search:↓

Tofacitinib can temporarily improve hair growth in alopecia universalis, but its effectiveness may decrease over time.

CD2 might be a new treatment target for patchy alopecia areata.

New insights show Lichen Planopilaris is a rare, scarring hair loss condition, hard to treat, mainly affecting middle-aged women, and significantly impacts mental health.

A woman's vitiligo improved with tofacitinib treatment, and her skin color remained even after stopping the medication, but there are concerns about cancer risk.

Higher granulysin levels in the blood are linked to more severe hair loss in alopecia areata patients, and these levels decrease after effective treatment.

Higher antigliadin antibodies are linked to more severe alopecia areata, suggesting screening for celiac disease in these patients.

Higher levels of IL-17A and IL-2 are linked to alopecia areata.

Higher antigliadin antibody levels are linked to alopecia areata severity.

ALA-PDT is effective and safe for chronic X-ray dermatitis, providing complete or partial remission.

Biologics and JAK inhibitors may improve treatment for scarring alopecias.

Oral methylprednisolone pulse therapy helped an 11-year-old regrow 80% of his hair in six months.

Alopecia Areata might be linked to Crohn's disease.

Higher air pollution increases the risk of alopecia areata.

A protein combining parathyroid hormone and collagen helped hair regrow in mice with a hair loss condition.

No link between scalp patterns and alopecia severity in children, but more severe cases often had nail abnormalities.

PRP and cell therapies may help with hair loss, but more research is needed.

Certain mutations in the PADI3 gene may increase the risk of developing a type of scarring hair loss common in women of African descent.

Microneedling with triamcinolone helps hair regrowth in ophiasis alopecia areata.

Secukinumab can cause hair loss, which may improve after stopping the medication.

A man had both alopecia areata and lichen planus, which is uncommon.

Oral tofacitinib shows promise in treating atopic dermatitis and alopecia areata, but only slight improvement in vitiligo.

Lower CD200R1 on certain immune cells is linked to more severe rheumatoid arthritis and immune imbalance.

Regenerative therapies show promise for treating vitiligo and alopecia areata.

Cholesterol-related compounds can stop hair growth and cause inflammation in a type of scarring hair loss.

Higher interleukin-15 levels are linked to more severe alopecia areata, but not to age or gender.

Janus Kinase Inhibitors are promising new treatments for various skin conditions due to their effectiveness and safety.

Alopecia Areata patients have low zinc and high copper levels.

Thyroid tests may not be needed for all vitiligo and alopecia areata patients unless thyroid disease symptoms appear.

Oxidative stress is linked to mild patchy alopecia areata.

Alopecia areata causes patchy hair loss and involves immune system disruptions.